Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer
Androgen receptor signaling inhibitor (ARSI) therapy plays an important role in treating advanced prostate cancer. However, in Thailand, the efficacy and safety data of ARSI therapy remain limited. This study aimed to assess the efficacy and safety of ARSI therapy to treat patients with metastatic c...
Saved in:
Main Authors: | Jukapun Yoodee (Author), Chiraphon Detma (Author), Onuma Lappanawan (Author), Worachaya Pengthina (Author) |
---|---|
Format: | Book |
Published: |
Faculty of Pharmacy, Mahidol University,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sequential versus concomitant treatment of androgen receptor signaling inhibitors and docetaxel for metastatic hormone-sensitive prostate cancer: an network meta-analysis
by: Chun Xing Li, et al.
Published: (2024) -
Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer
by: Huina Wu, et al.
Published: (2024) -
Practical implications of androgen receptor inhibitors for prostate cancer treatment
by: Fabio Campodonico, et al.
Published: (2024) -
The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells
by: Alastair H. Davies, et al.
Published: (2016) -
Splice variants of androgen receptor and prostate cancer
by: Orazio Caffo, et al.
Published: (2016)